ADARx Pharmaceuticals Inc. (Ticker: ADRX US) is a U.S. late-stage biotechnology company developing RNA-targeted therapeutics across complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic diseases, including obesity. The company has developed technologies designed to selectively control the expression of disease-related targets and is advancing a pipeline of RNA therapeutic candidates. ADARx also has a collaboration and license option agreement with AbbVie covering siRNA therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

ADARx plans to list on Nasdaq on September 25, 2026, following expected pricing on September 24. The company is offering 21.875 million shares at $15-$17 per share, representing an IPO size of approximately $350 million at the midpoint. The offering consists entirely of primary shares, with proceeds therefore going to the company before fees and expenses. J.P. Morgan, Morgan Stanley, TD Cowen and UBS are acting as bookrunners.

Bamboo Insurance Services (Ticker: BMB US) is a U.S. homeowners insurance business that uses technology and AI to help price policies, assess risk and manage claims. The company operates as a managing general underwriter (MGU), meaning it handles much of the insurance process while partner insurance carriers provide the capital and ultimately bear the claims risk.

Bamboo, which is incorporated in Delaware and backed by CVC, plans to list on the New York Stock Exchange on September 23, 2026. Selling shareholders are offering 35 million shares at $18.00 to $20.00 each, implying proceeds of approximately $665 million at the midpoint and up to $700 million at the top of the range. The offering implies an estimated market capitalization of around $3.0 billion, while Reuters reported a fully diluted valuation of up to approximately $3.2 billion.

All shares in the IPO are being sold by existing shareholders, so Bamboo itself will not receive any proceeds from the offering. J.P. Morgan, Morgan Stanley, Deutsche Bank Securities, Evercore ISI and Wells Fargo Securities are managing the IPO.

Ligent Technologies Inc. (Ticker: 9856 HK) is a Chinese semiconductor and optical communications company that develops products used in high-speed data networks, including optical transceivers, chips and network terminals. Its technology is designed in part for AI-driven computing networks, where large amounts of data need to move quickly between servers and data centers. The company serves customers globally.

Ligent plans to list on the Hong Kong Stock Exchange on September 22, 2026. The company is offering approximately 172.01 million new shares at HKD 32.96 per share, raising about HKD 5.67 billion, or approximately $723 million. The offering implies a market capitalization of around $4.1 billion.

All shares in the IPO are primary shares, meaning the proceeds will go to Ligent rather than existing shareholders. The offering also includes a 15% greenshoe option. CLSA, Citigroup Global Markets Asia, Futu Securities International and GF Securities Hong Kong Brokerage are among the managers of the IPO.

Transwarp (Ticker: 6727 HK) is a Chinese enterprise software company providing AI and big data infrastructure to corporate and government customers. Its software helps organizations store, manage and analyze large amounts of data, build AI applications and run cloud-based data systems. The company serves more than 1,800 customers across industries including finance, government, energy, healthcare, transportation and manufacturing, and says repeat purchases from existing customers accounted for more than 70% of revenue on average from 2023 through the first quarter of 2026.

Transwarp plans to list on the Hong Kong Stock Exchange on September 21, 2026, with an IPO raising approximately $88 million and an estimated market capitalization of about $948 million. According to Frost & Sullivan, Transwarp was China’s fifth-largest AI infrastructure software provider by revenue in 2025, with a 2.7% market share, and the country’s largest independent provider in the sector.

The company is also expanding internationally, with subsidiaries in Hong Kong, Singapore and Canada and customers in Singapore and the Middle East. BOCOM International, CMB International and several other securities firms are managing the offering.

Innovaero Technologies Ltd (Ticker: INN AU) is an Australian aerospace and defense manufacturer specializing in uncrewed aerial systems, composite aerostructures and loitering munitions, including its OWL family of precision systems. The company plans to list on the Australian Securities Exchange on September 18, 2026. Innovaero is offering 80 million primary shares at A$0.50 per share, raising A$40 million (approximately $28 million). The offering implies a market capitalization of approximately $112 million. According to published information, IPO proceeds are intended to support a new Jandakot R&D and manufacturing facility, expand sovereign drone production capacity and advance development of the OWL munitions portfolio. The offering consists entirely of primary shares. Canaccord Genuity Australia Ltd and Euroz Hartleys Ltd are managing the IPO.

Electra Therapeutics (Ticker: ETRA US) is a U.S. biotechnology company developing new medicines for immune-related diseases and cancer. Its treatments are designed to target and remove specific immune cells that contribute to disease, rather than broadly suppressing the immune system.

The company plans to list on Nasdaq on September 18, 2026. Electra priced its IPO at $15.00 per share and increased the offering to approximately 23.33 million shares, raising about $350 million. The IPO gives the company an estimated market capitalization of approximately $941 million.

Electra’s main drug candidate, ipsoprubart, is being tested in a late-stage Phase 2/3 clinical trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and potentially life-threatening condition involving excessive immune-system activation. The company is also developing ELA822 for immune and inflammatory diseases involving T cells.

Jefferies, TD Cowen, Evercore ISI and Cantor are managing the IPO.

Orion180 (Ticker: OIG US) is an American insurance company focused on homeowners and residential flood insurance, including excess and surplus lines coverage across 14 U.S. states. The Florida-based company plans to list on Nasdaq on September 18, 2026, with the IPO scheduled to price on September 17. Orion180 plans to offer 20 million shares at $15–$17 each, raising up to approximately $340 million and implying a valuation of around $1.7 billion.

Founded in 2018 by Kenneth Gregg, the company’s key markets include Texas, California and Florida. Orion180 generated approximately $601 million of managed premiums written during the 12 months ended June 30, 2026. RBC Capital Markets, UBS Investment Bank and Raymond James are serving as lead book-running managers for the offering.

Oliver Corporation (Ticker: 619A JP) is a Japanese commercial services company providing end-to-end interior solutions, spanning planning, design, consulting, project management, furniture manufacturing and interior construction. The company serves offices, hotels, restaurants, retail locations, healthcare facilities and other commercial and public spaces, supported by more than 100 designers. Oliver plans to list on the Tokyo Stock Exchange Standard Market on September 16, 2026.

The IPO was priced at JPY 305 per share, at the top of the JPY 295-305 range. The offering comprises approximately 74.1 million shares, raising approximately JPY 22.6 billion (approximately $142 million), before a potential 11.1 million-share overallotment. The offering consists entirely of secondary shares, with no primary shares being issued, meaning the proceeds from the base offering will go to selling shareholders rather than the company. The implied market capitalization at the offer price is approximately JPY 30.5 billion, or around $191 million.

Oliver’s largest shareholders include private equity-related entities Integral No. 4 Investment Limited Partnership, Initiative Delta IV L.P., Innovation Alpha IV L.P. and Integral Corporation. Daiwa Securities and Nomura Securities are the lead managers of the offering.

KOMPEITO Inc. (Ticker: 618A JP) is a Japanese food services company focused on workplace food and employee welfare solutions. Its core “OFFICE DE YASAI” service provides healthy meals, including salads and boxed meals, through refrigerators and freezers installed in offices. The company also operates in the United States through subsidiaries including KOMPEITO USA Inc.

KOMPEITO plans to list on the Tokyo Stock Exchange Growth Market on September 11, 2026. The IPO was priced at JPY 1,600 per share, at the top of the JPY 1,560-1,600 range. The offering comprises approximately 4.19 million shares, raising approximately JPY 6.70 billion (approximately $42 million), before a potential 628,200-share overallotment. Approximately 98.8% of the offering consists of secondary shares, with only 50,000 primary shares issued by the company. The implied market capitalization at the offer price is approximately JPY 15.84 billion, or around $99 million. SBI Securities is the lead manager.

Shenzhen Longsys Electronics Co., Ltd. (Ticker: 9976 HK) is a Chinese semiconductor memory products company that designs, develops, back-end manufactures and sells storage and memory products for consumer, enterprise and industrial applications. The company operates the FORESEE, Zilia and Lexar brands and does not manufacture memory wafers, instead sourcing wafers and controller chips from third-party suppliers.

Shenzhen Longsys plans to list on the Hong Kong Stock Exchange on September 8, 2026. The IPO is priced at HKD 236.00 per share, below the indicated HKD 240.60 range, with approximately 26.08 million shares offered. The base offering is expected to raise approximately HKD 6.15 billion, or approximately $785 million. All shares in the base offering are primary shares, with a 15% greenshoe covering approximately 3.91 million additional shares.

The offering is being managed by firms including ABCI Capital, CLSA, China Securities International, Citigroup Global Markets Asia and Futu Securities International.

Medcaptain Medical Technology Co Ltd (Ticker: 2041 HK) is a Chinese medical device company providing products across life support, minimally invasive intervention and in vitro diagnostics. Its portfolio includes infusion systems, endoscopic products, diagnostic analyzers and related consumables, with products distributed in more than 140 countries and regions and used in over 6,000 hospitals in China.

Medcaptain plans to list on the Hong Kong Stock Exchange on September 7, 2026. The company is offering approximately 38.91 million H shares at HKD 15.42 per share, raising approximately HKD 600 million (approximately $77 million). The offering consists entirely of primary shares. Based on the offer terms, Medcaptain is valued at approximately $943 million at the IPO price.

The company operates five R&D centers and six manufacturing centers across China and the UK. Revenue increased from RMB1.31 billion in 2023 to RMB1.62 billion in 2025, while gross margin rose to 53.7% in 2025. Medcaptain reported net profit of RMB50.7 million in 2025.

Mech-Mind Robotics Technologies Co Ltd (Ticker: 9615 HK) is a Chinese industrial robotics and embodied AI company providing intelligent robot components and integrated hardware-software systems. Its products use 3D vision, deep learning and AI-based motion planning to enable robots to perceive, interpret and interact with complex industrial environments. The company serves industries including automotive, new energy, consumer electronics, logistics and general manufacturing, with products sold in almost 50 countries and regions.

Mech-Mind plans to list on the Hong Kong Stock Exchange on September 1, 2026. The company is offering 23.14 million H shares at an expected price range of HKD 95.30 to HKD 101.70 per share, seeking to raise up to approximately HKD 2.35 billion (approximately $300 million). The offering consists entirely of primary shares and includes a 15% greenshoe option for approximately 3.47 million additional shares. CLSA, China Securities International, Daiwa Capital Markets Hong Kong and Futu Securities International are among the offering managers.

SHEIN Global Holdings Ltd (Ticker: 625 HK) is a Chinese global online fast-fashion and lifestyle retailer selling a broad range of affordable, trend-driven clothing, accessories, beauty and lifestyle products, supported by a data-driven, on-demand supply chain designed to rapidly introduce new styles. The company served approximately 273 million active customers across around 160 markets in 2025. Founded in China and headquartered in Singapore, SHEIN plans to list on the Hong Kong Stock Exchange on September 1, 2026.

According to published terms, SHEIN plans to offer approximately 280 million Class B shares at HKD47.60-HKD49.50 per share, raising up to approximately HKD13.86 billion ($1.77 billion). At the top of the range, the IPO would value the company at around $26.8 billion. The offering consists entirely of primary shares and includes a 15% greenshoe option of approximately 42 million shares. Goldman Sachs, Morgan Stanley and JPMorgan are among the banks backing the offering.

Ingenic Semiconductor Co., Ltd. (Ticker: 3223 HK) is a Chinese fabless semiconductor company developing memory, computing and analog ICs for automotive electronics, industrial and medical applications, AIoT and intelligent security devices. Its portfolio includes DRAM, SRAM, NOR and NAND Flash, intelligent vision SoCs, embedded processors, AI-MCUs and analog ICs.

Ingenic plans to list its H shares on the Hong Kong Stock Exchange on August 25, 2026. The company is offering approximately 31.29 million primary shares at HKD 102.80 per share, raising approximately HKD 3.22 billion (approximately $410 million). The offering also includes a 15% greenshoe option covering about 4.69 million additional shares.

The company operates a fabless model, focusing on R&D and IC design while outsourcing manufacturing and semiconductor assembly and testing to foundry and OSAT partners. According to the prospectus, Ingenic ranked among leading global suppliers in several semiconductor categories in 2025, including niche DRAM, SRAM, NOR Flash and IP-camera SoCs.

Kido Industrial Co., Ltd. (Ticker: 282620 KQ) is a South Korean manufacturer of high-performance outdoor, motorcycle and fashion apparel for global brands, with expertise in technical waterproof garments and complex textile manufacturing. The company operates production facilities across Vietnam, Bangladesh, Indonesia and Myanmar.

Kido plans to list on KOSDAQ on August 21, 2026, offering 1.7 million shares at KRW 28,400 per share, raising approximately KRW 48.3 billion (approximately $33 million). The offering consists of 1.35 million newly issued shares and 350,000 existing shares sold by shareholders. At the IPO price and based on 5.84 million shares outstanding after the offering, Kido would have an implied market capitalization of approximately $113 million. Founded in 1980 and headquartered in Seoul, Kido generated KRW 346.6 billion of revenue and KRW 35.3 billion of net income in 2025. Mirae Asset Securities is the lead manager, with Samsung Securities participating as an underwriter.

Lyntris, Inc. (Ticker: LYNX US) is a U.S. defense technology company providing connectivity solutions for military customers, including the U.S. Department of Defense and U.S. allies. Its offerings span sensor architecture, sensor hardware and data software platforms used in missile defense, maritime domain awareness, and space ISR and communications missions.

The Delaware-incorporated company plans to list on the NYSE on August 19, 2026, offering 24 million shares at $19.00 to $22.00 each. At the $20.50 midpoint, the IPO would raise approximately $492 million and imply a market capitalization of around $2.4 billion. Lyntris was formed in 2026 through the combination of Accelint and Vitesse, two businesses created by Trive Capital through a series of mergers. For the 12 months ended June 30, 2026, Lyntris reported revenue of approximately $451 million and a net loss of approximately $12 million.

Ingenia Therapeutics (Ticker: 952509 KS) is a U.S.-based biotechnology company developing treatments that repair and protect small blood vessels damaged by disease. Its drug candidates are being studied for retinal diseases, chronic kidney disease, glaucoma, cancer and pulmonary hypertension.

Ingenia plans to list on South Korea’s KOSDAQ market on August 18, 2026. The company will offer 5 million new shares at KRW 12,000 per share, raising KRW 60 billion, or approximately $41 million. The offering values the company at around $409 million after listing. Samsung Securities is the sole lead underwriter.

According to published terms, the IPO proceeds will be used to advance clinical trials, develop additional drug candidates and expand partnerships with global pharmaceutical and biotechnology companies. Ingenia’s lead retinal disease treatment, IGT-427, was licensed to EyeBio in 2022. EyeBio was later acquired by Merck & Co., which is now leading late-stage clinical development of the treatment.

Tactical Resources Corp. (Ticker: TREO US) is a Canadian-domiciled rare earth elements exploration and development company focused on building a U.S. supply chain for critical minerals. The company is advancing the Peak Project in Hudspeth County, Texas, and is also pursuing rare earth processing and separation technologies. Tactical Resources plans to begin trading on the Nasdaq Capital Market on August 18, 2026, following completion of its business combination with Plum Acquisition Corp. III.

The transaction is a de-SPAC combination rather than a conventional IPO. Tactical became a wholly owned subsidiary of a new parent company renamed Tactical Resources Corp. Following a four-for-one share consolidation effective August 17, approximately 13.6 million shares are expected to be outstanding. Tactical shareholders received New PubCo shares at a deemed pre-consolidation value of $10.00 per share, equivalent to $40.00 per share after the consolidation, implying an estimated reference valuation of approximately $545 million. The announcement did not specify a new primary share offering or associated proceeds. Plum’s warrants were also consolidated four-for-one, with the exercise price adjusted to $46.00, but will not be Nasdaq-listed.

Londian Wason New Energy Tech (Ticker: FOIL US) is a Cayman Islands-incorporated, China-based producer of electrolytic copper foil used in lithium-ion EV batteries, as well as flexible copper-clad laminates, electric energy meters and energy storage systems. The company is headquartered in Shenzhen and operates manufacturing facilities across China, with an additional plant under construction in Malaysia. Its customers include CATL, BYD, LG Energy Solution, Samsung SDI and Panasonic.

Londian Wason plans to list on the NYSE on August 12, 2026, offering approximately 3.57 million American Depositary Shares at a price range of $20.00 to $22.00 per ADS. Each ADS represents five ordinary shares. At the $21.00 midpoint, the IPO is expected to raise approximately $75 million. The company’s estimated market capitalization is around $1.6 billion. Cantor, Huatai Securities, CMB International, US Tiger Securities and Fortune (HK) Securities are joint managers of the offering.

NASN Intelligent Tech (Zhejiang) Co., Ltd. (Ticker: 2261 HK) is a Chinese intelligent-driving motion-control technology company specializing in brake-by-wire systems, chassis electronic controls and steering components designed to improve vehicle safety, comfort and efficiency. Founded in 2016 and based in Hangzhou, China, NASN plans to list on the Hong Kong Stock Exchange on August 7, 2026.

The company is offering 57.59 million H shares at an expected price range of HK$10.42 to HK$11.18 per share, seeking to raise up to approximately HK$644 million, equivalent to approximately $82 million. The offering comprises entirely primary shares and includes a 15% greenshoe facility covering approximately 8.64 million additional shares.

NASN is backed by investors including Contemporary Amperex Technology and Hillhouse Investment. The offering is being managed by BOCI Asia, Haitong International Securities, Orient Securities Hong Kong, SDICS Securities Hong Kong and other advisers.

BlossomHill Therapeutics, Inc. (Ticker: BLSM US) is an American clinical-stage biotechnology company developing new cancer treatments. Its research focuses on medicines designed to target genetic changes that help certain cancers grow, including forms of lung cancer, leukemia and other tumors that can be difficult to treat.

BlossomHill plans to list on Nasdaq on August 7, 2026, following expected pricing on August 6. The company is offering 7,812,500 newly issued shares at a price of $15.00 to $17.00 per share. At the midpoint of the range, the IPO would raise approximately $125 million. Because all shares are primary, the proceeds will go to the company rather than existing shareholders.

The company’s most advanced drug candidates are being studied for a type of lung cancer that has become resistant to existing treatments, as well as for certain blood cancers. BlossomHill also has an earlier-stage drug candidate aimed at tumors linked to KRAS mutations, which are common genetic drivers in several cancers.

BlossomHill previously raised $100 million in a Series B financing. J.P. Morgan, Leerink Partners and Guggenheim are serving as bookrunners.

Latigo Biotherapeutics (Ticker: LTGO US) is a U.S. biotechnology company developing non-opioid treatments for short-term and long-term pain. Its medicines are designed to block pain signals in the body without acting on the brain, which may reduce the addiction risks linked to opioid painkillers.

The company’s lead drug, LTG-001, is being developed for moderate to severe acute pain, including pain after surgery, and is expected to begin Phase 3 testing in the second half of 2026. A second drug, LTG-321, is being tested for chronic pain caused by conditions such as knee osteoarthritis.

Latigo plans to list on Nasdaq on August 7, 2026. The company is offering 16 million shares at $16.00 to $18.00 each and aims to raise approximately $272 million at the midpoint of the range. The IPO implies an estimated market value of around $1.0 billion. Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities are managing the offering. Latigo was founded in 2018 and has not yet generated product revenue.

Braveheart Bio, Inc. (Ticker: BRVE US) is an American clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Incorporated in Delaware and headquartered in San Francisco, the company’s lead candidate, BHB-1893, is being evaluated for obstructive and non-obstructive hypertrophic cardiomyopathy.

Braveheart Bio plans to list on Nasdaq on August 6, 2026. The company is offering 18.8 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $300 million at the $16.00 midpoint. Its estimated market capitalization at the offering is around $1.1 billion.

BHB-1893 was discovered and initially developed by China-based Jiangsu Hengrui Pharmaceuticals, from which Braveheart Bio obtained exclusive licensing rights. The company plans to begin a global Phase 3 trial in obstructive hypertrophic cardiomyopathy in the second half of 2026 and another Phase 3 trial in non-obstructive disease in the first half of 2027. Braveheart Bio has not generated product revenue. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are managing the offering.

Attovia Therapeutics, Inc. (Ticker: ATTO US) is an American clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated diseases using its licensed ATTOBODY nanobody-based platform. Incorporated in Delaware and headquartered in San Carlos, California, the company has no approved products or product-sales revenue.

Attovia plans to list on Nasdaq on August 5, 2026. The company is offering 12.5 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $200 million at the $16.00 midpoint. Its estimated market capitalization at the offering is approximately $616 million.

The company’s lead candidate, ATTO-1310, targets IL-31 and completed dosing in a Phase 1 trial involving healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026. Its pipeline also includes ATTO-2306, a bispecific candidate targeting IL-13 and IL-31, and ATTO-1091, a trispecific candidate being developed for inflammatory bowel disease. Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are managing the offering.

Apnimed (Ticker: APMD US) is an American Phase 3 pharmaceutical company developing oral treatments for obstructive sleep apnea. Its sole clinical drug candidate, AD109, also known as Oxnimbi, is a fixed-dose combination of a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor designed to improve upper-airway muscle activity and prevent airway collapse during sleep. The company has evaluated Oxnimbi in approximately 1,300 patients across several Phase 3 trials.

Apnimed plans to list on Nasdaq on July 31, 2026. The Delaware-incorporated company intends to offer 10 million shares at a price range of $14.00 to $16.00 per share, raising approximately $150 million at the midpoint. The offering implies an estimated market capitalization of approximately $570 million. BofA Securities, Evercore ISI, Cantor and LifeSci Capital are serving as joint managers.

Zhongji Innolight Co., Ltd. (Ticker: 3308 HK) is a Chinese telecommunications equipment company that provides optical interconnect solutions for cloud computing, data centers and AI infrastructure. Its principal products are optical transceivers, which convert electrical and optical signals to support high-speed data transmission. The company’s product portfolio includes 400G, 800G and 1.6T transceivers, including products using silicon photonics technology.

Zhongji Innolight plans to list on the Hong Kong Stock Exchange on July 30, 2026. According to published terms, the company expects to offer 54.5 million primary shares at HK$1,010 per share, raising approximately HK$55.05 billion, or around $7.02 billion. The underwriters have a 15% over-allotment option covering approximately 8.18 million additional shares.

The offering is managed by a syndicate including ABCI Securities, China Galaxy International Securities, Citigroup, China International Capital Corporation, GF Securities, Goldman Sachs, Haitong International, HSBC, Morgan Stanley, Zero2IPO Securities and Zhongtai International Securities.

Reformation, Inc. (Ticker: REF US) is a US-based apparel company focused on women’s clothing and accessories, with sustainability positioned as a core part of its brand and operating model. Founded in 2009, the company reported more than $500 million in net revenue and over one million active customers in 2025, following a 34% revenue CAGR from 2015 to 2025.

Reformation is expected to begin trading on the New York Stock Exchange on July 30, 2026, following pricing on July 29. The IPO consists of 14,062,500 shares at an indicated price range of $15.00 to $17.00 per share, implying an offer size of approximately $225 million at the midpoint. Around 67% of the base offering comprises primary shares issued by the company, while 33% consists of secondary shares sold by existing shareholders. The 2,109,375-share greenshoe is entirely secondary.

J.P. Morgan is lead-left bookrunner, with Morgan Stanley serving as joint active bookrunner and stabilization agent.

Jersey Mike’s Subs (Ticker: JMKE US) is a US-based fast-casual restaurant franchisor operating more than 3,300 locations across the United States and Canada. Founded in 1956 as Mike’s Subs in Point Pleasant, New Jersey, the company’s franchise network primarily serves made-to-order submarine sandwiches.

Jersey Mike’s plans to list on the New York Stock Exchange on July 30, 2026, following pricing on July 29. The IPO comprises 43,478,261 shares at an indicated price range of $21.00 to $25.00 per share, representing an offer size of approximately $913 million to $1.09 billion, or approximately $1 billion at the midpoint.

Approximately 32% of the shares in the offering are primary shares issued by the company, with the remaining 68% consisting of secondary shares sold by existing shareholders. Morgan Stanley, J.P. Morgan and Jefferies are acting as global coordinators and joint bookrunning managers. Morgan Stanley is also serving as stabilization agent.

iGrid Solutions Inc. (Ticker: 603A JP) is a Japanese energy and utilities company developing and operating platforms for distributed energy resources, onsite solar power plants, storage batteries, EV-related solutions, energy trading, and related consulting and GX services. The company is domiciled in Japan and offers its services throughout the country.

iGrid Solutions plans to list on the Tokyo Stock Exchange Growth Market on July 29, 2026. According to published terms, the company plans to offer 10.74 million shares at an expected price range of JPY 740 to JPY 770 per share, raising approximately JPY 8.27 billion, or about $51 million. The offering consists of 2.69 million primary shares, representing 25.04% of the offering, and 8.05 million secondary shares, representing 74.96%, with a 15% greenshoe facility of 1.61 million shares.

The offering is managed by Nomura Securities. According to company materials, iGrid Solutions focuses on local production and consumption of renewable energy, including rooftop solar installations, surplus electricity circulation using AI forecasting, and battery/EV solutions for corporate facilities.